Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?

Cyclacel Pharmaceuticals (NASDAQ: CYCC ) stock is falling on Tuesday but it’s not due to any negative news from the clinical stage biopharmaceutical company. Instead, shares of CYCC stock are retreating after undergoing a rally on Monday. That rally came about after the company announced it had regained compliance with Nasdaq Exchange listing standards.

Cyclacel Pharmaceuticals is no longer in danger of being delisted after managing to boost its share price above the $1 minimum bid requirement. That news excited investors yesterday and saw shares of CYCC stock close out normal trading hours up 28.1%. CYCC Stock Movement on Tuesday It makes sense that shares of CYCC stock would give up some of the gains it saw on yesterday’s news.

Shares are starting to settle after coming off that high and the hype diminishes. It’s worth mentioning that only about 59,000 shares of the company’s stock have changed hands as of this writing. That’s still below its daily average trading volume of about 125,000 shares. CYCC stock is down 9.4% as of Tuesday morning but is still up 17.7% since the start of the year.

Investors seeking out even more of the hottest stock market news today are in the right place! We have all of the latest stock market stories worth reading about on Tuesday! That includes everything happening with shares of Grifols (NASDAQ: GRFS ) stock, Elicio Therapeutics (NASDAQ: ELTX ) stock and Sentage (NASDAQ: SNTG ) stock today.

You can catch up on these topics at the links below! More Stock Market News for Tuesday Why Is Grifols (GRFS) Stock Down 38% Today? Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today? Why Is Sentage (SNTG) Stock Up 86% Today? On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.

The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines . With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day.

That’s because these “ penny stocks ” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low volume stock that may be affected by our commentary, we demand that InvestorPlace.com ’s writers disclose this fact and warn readers of the risks.

Read More: Penny Stocks — How to Profit Without Getting Scammed.